Suppr超能文献

实验性肾病综合征中肾小球nephrin和足突蛋白的丰度:抗蛋白尿疗法的不同作用

Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies.

作者信息

Nakhoul Farid, Ramadan Rawi, Khankin Eliyahu, Yaccob Afif, Kositch Zoya, Lewin Moshe, Assady Suheir, Abassi Zaid

机构信息

Dept. of Physiology and Biophysics, Faculty of Medicine, Technion, P.O. Box 9649, Haifa, 31096, Israel.

出版信息

Am J Physiol Renal Physiol. 2005 Oct;289(4):F880-90. doi: 10.1152/ajprenal.00451.2004. Epub 2005 Jun 7.

Abstract

Nephrotic syndrome (NS) is a clinical state characterized by massive proteinuria, hypoalbuminemia, and eventual edema formation. Although the mechanisms underlying this phenomenon are not yet fully clarified, it is well accepted that nephrin and podocin are involved in the development of proteinuria. The effects of early treatment with various antiproteinuric therapies on proteinuria and glomerular staining of nephrin and podocin in rats with experimental NS have not been previously studied. Proteinuria and glomerular nephrin and podocin immunofluorescence were examined in rat kidneys with adriamycin-induced NS and the effects of antiproteinuric drug therapies during 5 wk with enalapril, losartan, alone or in combination, omapatrilat, and mycophenolate mofetil on these parameters were assessed. Injection of adriamycin caused a significant increase in daily (from 21.8 +/- 1.4 to 983.1 +/- 45.8 mg/day, P < 0.01) and cumulative protein excretion (from negligible values to 22,490 +/- 931 mg, P < 0.001) during 5 wk. Early treatment with enalapril significantly decreased the daily (641.7 +/- 82.4 mg/day, P < 0.0023) and cumulative proteinuria (15,727 +/- 2,204 mg, P < 0.001). A similar effect, although to a lesser extent, was obtained after omapatrilat treatment: cumulative proteinuria was reduced to 18,706 +/- 1,042 mg, P < 0.001. In contrast, losartan treatment did not significantly influence the cumulative proteinuria that remained comparable (20,351 +/- 1,360 mg, P > 0.05) to that observed in untreated NS rats. Unexpectedly, when losartan was given in combination with enalapril, it abolished the beneficial effects of the latter. Pretreatment with mycophenolate mofetil exerted a moderate antiproteinuric effect, which appeared only during the last week of the experimental treatment. Nephrotic rats exhibited severe disruption of slit diaphragm structure as seen by rapid and profound loss of nephrin and podocin. Beneficial effects of enalapril, omapatrilat, and mycophenolate mofetil paralleled the preservation of nephrin, as determined immunohistochemically, and enabled prediction of significant antiproteinuric responses. Enalapril alone or in combination with losartan resulted in significant preservation of podocin. Pretreatment with enalapril, and to a lesser extent omapatrilat, is superior to losartan in reducing proteinuria in NS rats. A combination of ACE inhibitors with ANG II receptor blockers does not provide any advantageous antiproteinuric therapy in these animals. Nephrin loss is an indication of proteinuria in NS and the antiproteinuric effects of ACE inhibitors, vasopeptidase inhibitors, and mycophenolate mofetil attenuate this reduction. Not all the drugs which restore podocin reduce urinary protein in NS.

摘要

肾病综合征(NS)是一种以大量蛋白尿、低白蛋白血症及最终形成水肿为特征的临床状态。尽管这一现象背后的机制尚未完全阐明,但人们普遍认为nephrin和足突蛋白(podocin)参与了蛋白尿的发生发展。此前尚未研究过各种抗蛋白尿疗法早期治疗对实验性NS大鼠蛋白尿以及nephrin和足突蛋白肾小球染色的影响。在阿霉素诱导的NS大鼠肾脏中检测蛋白尿以及肾小球nephrin和足突蛋白免疫荧光,并评估5周期间依那普利、氯沙坦单独或联合使用、奥美帕替拉(omapatrilat)及霉酚酸酯对这些参数的影响。注射阿霉素导致5周期间每日蛋白尿(从21.8±1.4增至983.1±45.8mg/天,P<0.01)及累积蛋白排泄量(从可忽略不计增至22490±931mg,P<0.001)显著增加。依那普利早期治疗显著降低了每日蛋白尿(641.7±82.4mg/天,P<0.0023)及累积蛋白尿(15727±2204mg,P<0.001)。奥美帕替拉治疗后也有类似效果,尽管程度较轻:累积蛋白尿降至18706±1042mg,P<0.001。相比之下,氯沙坦治疗对累积蛋白尿无显著影响,其累积蛋白尿与未治疗的NS大鼠相当(20351±1360mg,P>0.05)。出乎意料的是,氯沙坦与依那普利联合使用时会消除依那普利的有益作用。霉酚酸酯预处理发挥了中度抗蛋白尿作用,且仅在实验治疗的最后一周出现。肾病大鼠表现出裂孔隔膜结构的严重破坏,表现为nephrin和足突蛋白迅速且显著丧失。免疫组织化学检测显示,依那普利、奥美帕替拉和霉酚酸酯的有益作用与nephrin的保留情况平行,且能够预测显著的抗蛋白尿反应。依那普利单独或与氯沙坦联合使用可显著保留足突蛋白。在降低NS大鼠蛋白尿方面,依那普利单独或与氯沙坦联合使用优于氯沙坦。在这些动物中,ACE抑制剂与血管紧张素II受体阻滞剂联合使用并不能提供任何有利的抗蛋白尿治疗。Nephrin丧失是NS中蛋白尿的一个指标,ACE抑制剂、血管肽酶抑制剂和霉酚酸酯的抗蛋白尿作用减弱了这种降低。并非所有恢复足突蛋白的药物都能降低NS中的尿蛋白。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验